CHROMAVISION MEDICAL SYSTEMS INC Form SC 13D/A

August 13, 2002

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)(1)

ChromaVision Medical Systems, Inc. (Name of Issuer)

Common Stock, \$0.01 Par Value Per Share
 (Title of Class of Securities)

17111P 10 4 (CUSIP Number)

N. Jeffrey Klauder, Esq.
800 The Safeguard Building, 435 Devon Park Drive
Wayne, PA 19087-1945
(610) 293-0600

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 9, 2002 (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box / /.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

(continued on following pages)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act.

CUSIP No. 17111P 10 4 13D Page 2 of 14

NAME OF REPORTING PERSON Safeguard Scientifics, Inc.

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON 23-1609753

2	CHECK THE	APPROPRIATE BOX 1	IF A MEME	BER OF A	A GROUP	(a) (b)	/	/
3	SEC USE ON	1LY				, ,		
4	SOURCE OF	FUNDS VC						
5		IF DISCLOSURE OF URSUANT TO ITEMS			NGS IS		/	/
6		P OR PLACE OF ORG	GANIZATIC	N				
NUMBER OF SHARES BENEFICIA			7	SOLE VO	OTING POWER			
OWNED BY EACH PERSON WI			8	SHARED	VOTING POWER 14,919,415			
			9	SOLE DI	ISPOSITIVE POW	√ER		
			10	SHARED	DISPOSITIVE H	POWER		
11	AGGREGATE	AMOUNT BENEFICIAL	LLY OWNED	BY EAC	CH REPORTING I	PERSON		
	1	4,919,415						
12	CHECK BOX CERTAIN SE	IF THE AGGREGATE HARES*	AMOUNT I	N ROW	(11) EXCLUDES		/ x	/
13		CLASS REPRESENTE	ED BY AMC	OUNT IN	ROW (11)			
14		EPORTING PERSON						
executive foundation or over w	e officers ons, trusts which they	egate of 45,915 sh and directors of s and limited part exercise shared v disclaims benefici	Safeguar nerships oting or	d Scier that a dispos	ntifics, Inc. are either consitive power.	and 50 ntrolle Safegu	1(c)(d by	
CUSIP No.	. 17111P 10) 4	13D			Pa	ge 3	of 14
1		EPORTING PERSON Safeguard Delaware	e, Inc.					
		R.S. IDENTIFICATI 52-2081181	ION NO. C	F ABOVE	E PERSON			
2	CHECK THE	APPROPRIATE BOX 1	IF A MEME	BER OF A	A GROUP	(a)	/	/
3	SEC USE ON	1LY				(b)	/	/
4	SOURCE OF	FUNDS						

AF

5	CHECK BOX IF DISCLOSURE OF REQUIRED PURSUANT TO ITEMS			NGS IS	/ /
6	CITIZENSHIP OR PLACE OF OF Delaware	RGANIZATI	ION		
NUMBER C SHARES BENEFICI		7	SOLE V	OTING POWER	
OWNED BY EACH REPORTIN	<u>'</u>	8	SHARED	VOTING POWER * 11,480,694	
PERSON	NG	9	SOLE D	ISPOSITIVE POWER	
		10	SHARED	DISPOSITIVE POW 10,519,772	ER
11	AGGREGATE AMOUNT BENEFICIA	ALLY OWN	ED BY EA	CH REPORTING PER	SON
	11,480,694				
12	CHECK BOX IF THE AGGREGATE EXCLUDES CERTAIN SHARES*	E AMOUNT	IN ROW	(11)	/ /
13	PERCENT OF CLASS REPRESENT 40.5%	CED BY AN	MOUNT IN	ROW (11)	
14	TYPE OF REPORTING PERSON CO				
*Pursuant to Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended, the filing persons may have acquired beneficial ownership of 960,922 shares of ChromaVision Medical Systems, Inc. common stock by virtue of voting agreements and irrevocable proxies which are described in Amendment No. 2 to Schedule 13D previously filed by Safeguard Scientifics, Inc.					
CUSIP No	o. 17111P 10 4	13D			Page 4 of 14
1	NAME OF REPORTING PERSON Safeguard Scienti	fics (De	elaware)	, Inc.	
	S.S. OR I.R.S. IDENTIFICAT 51-0291171	CION NO.	OF ABOV	E PERSON	
2	CHECK THE APPROPRIATE BOX	IF A MEN	MBER OF	A GROUP	(a) / /
3	SEC USE ONLY				(b) / /
4	SOURCE OF FUNDS AF				
5	CHECK BOX IF DISCLOSURE OF REQUIRED PURSUANT TO ITEMS			NGS IS	/ /
6	CITIZENSHIP OR PLACE OF OF Delaware	RGANIZAT	ION		
NUMBER C)F	7	SOLE V	OTING POWER	

SHARES	3 3		-0-		
BENEFICI OWNED BY EACH		8	SHARED VOTING POWER 3,438,721		
REPORTING PERSON		9	SOLE DISPOSITIVE POWE	R	
		10	SHARED DISPOSITIVE PO 3,438,721	WER	
11	AGGREGATE AMOUNT BENEFICI. 3,438,721	ALLY OWNI	ED BY EACH REPORTING PE	RSON	
12	CHECK BOX IF THE AGGREGAT CERTAIN SHARES*	E AMOUNT	IN ROW (11) EXCLUDES	/	/
13	PERCENT OF CLASS REPRESEN 13.6%	TED BY AI	MOUNT IN ROW (11)		
14	TYPE OF REPORTING PERSON CO				
CUSIP No	o. 17111P 10 4	13D		Page 5	of 14
1	NAME OF REPORTING PERSON Safeguard 98 Cap	ital, L.	Ρ.		
	S.S. OR I.R.S. IDENTIFICA 52-2081182	TION NO.	OF ABOVE PERSON		
2	CHECK THE APPROPRIATE BOX	IF A ME	,	a) /	/
3	SEC USE ONLY		(b) /	/
4	SOURCE OF FUNDS AF				
5	CHECK BOX IF DISCLOSURE O PURSUANT TO ITEMS 2(d) OR		PROCEEDINGS IS REQUIRED	/	/
6	CITIZENSHIP OR PLACE OF O	RGANIZAT	ION		
NUMBER C		7	SOLE VOTING POWER		
BENEFICI OWNED BY EACH		8	SHARED VOTING POWER		
REPORTIN PERSON	IG	9	SOLE DISPOSITIVE POWE	R	
		10	SHARED DISPOSITIVE PO	WER	
11	AGGREGATE AMOUNT BENEFICI	ALLY OWNI	ED BY EACH REPORTING PE	RSON	
12	CHECK BOX IF THE AGGREGAT	E AMOUNT	IN ROW (11) EXCLUDES		

CERTAIN SHARES* / /

- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0%
- 14 TYPE OF REPORTING PERSON PN

Page 6 of 14

The following information supplements and amends the information contained in the Schedule 13D and amendments thereto previously filed by Safeguard Scientifics, Inc. ("Safeguard") relating to the ownership by its subsidiaries of the common stock, \$0.01 par value per share, of ChromaVision Medical Systems, Inc., a Delaware corporation (the "Company"), listed on the cover pages of this amendment.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

Add the following to the end of Item 3:

On June 30, 2002, pursuant to the terms of the Series D Preferred Stock, the Company elected to pay the dividend on the Series D Stock in common stock and delivered to SDI 114,992 shares of common stock based on a per share value of \$1.786.

Pursuant to the terms of the Securities Purchase Agreement dated June ____, 2002, to which Safeguard Delaware, Inc. (SDI) and XL Vision, Inc. (XLV) were parties, SDI agreed to purchase from XLV the 699,870 shares of Company common stock owned by XLV. The transaction was subject to the approval of the United States Bankruptcy Court of the Southern District of Florida, in the matter of XL Vision, Inc., Debtor. The Bankruptcy Court approved the transaction on July 8, 2002, and on July 9, 2002, SDI purchased the 699,870 shares of Company common stock at a per share purchase price of \$1.585. Safeguard 98 Capital, L.P. had a pre-existing right to obtain from XLV 324,612 shares of Company common stock under the convertible note issued by XLV. Since XLV no longer owns shares of Company common stock, the convertible note held by Safeguard 98 Capital, L.P. will remain outstanding as a claim against the XLV bankruptcy estate although XLV no longer owns shares of Company common stock to deliver upon the conversion. The funds used in making such purchase came from the general working capital of Safeguard.

ITEM 4. PURPOSE OF TRANSACTION

Safeguard acquired the shares as part of its operating strategy to integrate its partner companies into a collaborative network that leverages its collective knowledge and resources. With the goal of holding its partner company interests for the long term, Safeguard uses these collective resources to actively develop the business strategies, operations and management teams of the Company and its other partner companies. Safeguard intends to review, from time to time, its interest in the Company's business, financial condition, results of operations and prospects, economic and industry conditions, as well as other developments and other acquisition opportunities. Based upon these considerations, Safeguard may seek to acquire additional shares of common stock of the Company on the open market or in privately negotiated transactions, or to dispose of all or a portion of its shares of the Company, subject to certain restrictions described in Amendment No. 2 to Schedule 13D.

Safeguard has a strategic relationship with the Company and, accordingly, one representative of Safeguard is currently a member of the Board of Directors of the Company. Safeguard anticipates that this strategic relationship will continue.

Other than as set forth in Item 3 or Item 4 of this statement or as disclosed in previous amendments to Schedule 13D, each Reporting Person currently has no plan or proposal which relates to, or may result in, any of the matters listed in Items 4(a) - (i) of Schedule 13D (although each Reporting Person reserves the right to develop such plans).

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Replace the disclosure previously contained in Item 5 with the following:

The table below sets forth the aggregate number of shares and percentage of the Company's outstanding shares beneficially owned by each Reporting Person as of July 9, 2002. The information contained in rows 6 through 11 on each of the cover pages hereto is hereby incorporated by reference into this Item 5.

Unless otherwise indicated in Schedule V annexed hereto, no Reporting Person or director or executive officer of a Reporting Person listed on Schedules II through IV annexed hereto has consummated any transaction in the Company's shares during the past sixty days other than as set forth herein.

Page 7 of 14

Beneficial Ownersh

	Number of Shares
	1.4.010.415
Safeguard Scientifics, Inc. (2)	14,919,415
Safeguard Delaware, Inc. (3)	11,480,694
Safeguard Scientifics (Delaware), Inc.	3,438,721
Safeguard 98 Capital L.P.	0

- (1) Calculations based upon 25,301,970 shares outstanding.
- (2) Includes the 7,523,977 directly held shares, the 2,955,745 shares of common stock currently issuable upon the conversion of the Series D Preferred Stock, and warrants to purchase 40,050 shares beneficially owned by Safeguard Delaware, Inc. (SDI) and the 3,438,721 shares beneficially owned by Safeguard Scientifics (Delaware), Inc. (SSD). Includes the 960,922 shares that may be beneficially owned by SDI by virtue of voting agreements and irrevocable proxies previously described in Amendment No. 2 to Schedule 13D. Safeguard is the sole stockholder of each of SDI and SSD. Safeguard and each of SDI and SSD have reported that Safeguard, together with each of SDI and SSD, respectively, have shared voting and dispositive power with respect to the shares beneficially owned by each of SDI and SSD, respectively. Excludes (i) an aggregate of 45,915 shares of common stock held by certain executive officers and directors of Reporting Persons and 501(c)(3) foundations, trusts and limited partnerships that are either controlled by them or over which they exercise shared voting or dispositive power, of which Safeguard disclaims beneficial ownership, (ii) 362,663 shares of common stock that SDI has the right to purchase from the Company under stockholder approval, and (iii) 4,151,294 additional shares of common stock issuable to SDI upon conversion of all of the outstanding shares of Series D Preferred Stock and/or exercise of the Series D Warrants upon stockholder approval.
- (3) Includes warrants to purchase 40,050 shares. Includes the 960,922

shares that may be beneficially owned by SDI by virtue of voting agreements and irrevocable proxies previously described in Amendment No. 2 to Schedule 13D. See Note 2.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

In addition to the agreements previously filed as exhibits to Schedule 13D and amendments thereto, SDI and XLV are parties to the Stock Purchase Agreement dated as of June $\underline{\hspace{1cm}}$, 2002, pursuant to which SDI acquired the shares set forth in Items 3 and 4 above from XLV.

Item 7. MATERIAL TO BE FILED AS EXHIBITS

EXHIBIT NO. DESCRIPTION

99.13 Stock Purchase Agreement dated as of June ____, 2002 between Safeguard Delaware, Inc. and XL Vision, Inc.

Page 8 of 14

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this schedule is true, complete and correct.

Date: August 2, 2002

Safeguard Scientifics, Inc.

By: /s/ N. Jeffrey Klauder

N. Jeffrey Klauder

Managing Director

Date: August 2, 2002

Safeguard Delaware, Inc.

By: /s/ N. Jeffrey Klauder

N. Jeffrey Klauder

Vice President

Date: August 2, 2002 Safeguard Scientifics (Delaware), Inc. By: /s/ N. Jeffrey Klauder

N. Jeffrey Klauder Vice President

Date: August 2, 2002 Safeguard 98 Capital L.P.

By: Safeguard Delaware, Inc.

Its: General Partner

By: /s/ N. Jeffrey Klauder

N. Jeffrey Klauder Vice President

Page 9 of 14

1. Safequard Scientifics, Inc.

Safeguard Scientifics, Inc., a Pennsylvania corporation ("Safeguard"), owns all of the outstanding capital stock of Safeguard Delaware, Inc., a Delaware corporation ("SDI"), and Safeguard Scientifics (Delaware), Inc., a Delaware corporation ("SSD"). Safeguard has an address at 800 The Safeguard Building, 435 Devon Park Drive, Wayne, PA 19087-1945. Safeguard is a leader in building and operating technology companies in three principal areas: business and IT services, software and emerging technologies. See Schedule II with respect to the executive officers and directors of Safeguard as of the date of this amendment to Schedule 13D.

2. Safeguard Delaware, Inc.

SDI is a wholly owned subsidiary of Safeguard. SDI is a holding company and has an office at 103 Springer Building, 3411 Silverside Road, P.O. Box 7048, Wilmington, DE 19803. SDI is the general partner of Safeguard 98 Capital L.P. ("Safeguard 98"), a Delaware limited partnership. Schedule III provides information about the executive officers and directors of SDI as of the date of this amendment to Schedule 13D.

3. Safeguard Scientifics (Delaware), Inc.

SSD is a wholly owned subsidiary of Safeguard. SSD is a holding company and has an office at 103 Springer Building, 3411 Silverside Road, P.O. Box 7048, Wilmington, DE 19803. Schedule IV provides information about the executive officers and directors of SSD as of the date of this amendment to Schedule 13D.

4. Safeguard 98 Capital L.P.

Safeguard 98 is a Delaware limited partnership with a principal place of business at 103 Springer Building, 3411 Silverside Road, P.O. Box 7048, Wilmington, DE 19803.

Page 10 of 14

SCHEDULE II

EXECUTIVE OFFICERS AND DIRECTORS OF SAFEGUARD SCIENTIFICS, INC.

Name	Present Principal Employment	Business Ad
EXECUTIVE OFFICERS* Anthony L. Craig	President, Chief Executive Officer and Director	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr

Michael F. Cola Managing Director, Corporate Operations

Safeguard Scienti

Wayne, PA 19087

Officer

Managing Director, Software

Managing Director and Chief Financial

Managing Director and General Counsel

Managing Director, Business & IT Services Safeguard Scienti

Robert D. Crowley

Christopher J. Davis

Anthony A. Ibarguen

N. Jeffrey Klauder

DIRECTORS*		wayne, PA 1900/
Robert E. Keith, Jr.	Managing Director of TL Ventures and President and CEO, Technology Leaders Management, Inc.	TL Ventures 700 Building 435 Devon Park Dr Wayne, PA 19087
Anthony L. Craig Vincent G. Bell, Jr.	Same as above President and Chief Executive Officer, Verus Corporation	Same as above Verus Corporation 5 Radnor Corporat Suite 520 Radnor, PA 19087
Walter W. Buckley, III	Chairman and CEO, Internet Capital Group, Inc.	Internet Capital 435 Devon Park Dr Building 600 Wayne, PA 19087
Robert A. Fox	President, R.A.F. Industries	R.A.F. Industries One Pitcairn Pl, 165 Township Line Jenkintown, PA 19
Jack L. Messman	Chairman, President & CEO, Novell, Inc.	Novell, Inc. 1800 South Novell Provo, Utah 84606
Russell E. Palmer	Chairman and CEO, The Palmer Group	The Palmer Group 3600 Market Stree Philadelphia, PA
John W. Poduska Sr.	Consultant	295 Meadowbrook R Weston, MA 02493-
* All Executive Officers and D	irectors are U.S. Citizens.	

800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

Safeguard Scienti

800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

Page 11 of 14

SCHEDULE III

EXECUTIVE OFFICERS AND DIRECTORS OF SAFEGUARD DELAWARE, INC.

Name	Present Principal Employment	Busin
EXECUTIVE OFFICERS*		
Anthony L. Craig	President, Safeguard Delaware, Inc.; President and CEO, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Christopher J. Davis	Vice President & Treasurer, Safeguard Delaware, Inc.; Managing Director and CFO, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
N. Jeffrey Klauder	Vice President & Assistant Secretary, Safeguard Delaware, Inc.; Managing Director and General Counsel, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
DIRECTORS* Deirdre Blackburn	Manager, Legal Systems & Corporate Secretary, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Joseph R. DeSanto	Director, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Tonya L. Zweier	Director, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

^{*} All Executive Officers and Directors are U.S. Citizens.

Page 12 of 14

SCHEDULE IV

EXECUTIVE OFFICERS AND DIRECTORS OF SAFEGUARD SCIENTIFICS (DELAWARE), INC.

Name	Present Principal Employment	Busines
EXECUTIVE OFFICERS*		
Anthony L. Craig	President, Safeguard Scientifics	Safeguard Scienti
	(Delaware), Inc.; President and CEO,	800 The Safeguard
	Safeguard Scientifics, Inc.	435 Devon Park Dr
		Wayne, PA 19087
Christopher J. Davis	Vice President & Treasurer, Safeguard	Safeguard Scienti

	Scientifics (Delaware), Inc.; Managing Director and CFO, Safeguard Scientifics, Inc.	800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
N. Jeffrey Klauder	Vice President & Assistant Secretary, Safeguard Scientifics (Delaware), Inc.; Managing Director and General Counsel, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
DIRECTORS* Deirdre Blackburn	Manager, Legal Systems & Corporate Secretary, Safeguard Scientifics, Inc.	Safeguard Scienti 800 The Safeguard 435 Devon Park Dr Wayne, PA 19087
Joseph R. DeSanto	Director, Safeguard Scientifics, Inc.	Safeguard Scienti

800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

Tonya L. Zweier Director, Safeguard Scientifics, Inc.

800 The Safeguard 435 Devon Park Dr Wayne, PA 19087

Safeguard Scienti

Page 13 of 14

SCHEDULE V

All of the following transactions were effected by the executive officers and directors of the Reporting Persons listed below, in brokers' transactions in the Nasdaq National Market.

Name	Date	Type of Transaction	Shares	Price Per Share
None				

Page 14 of 14

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.13	Stock Purchase Agreement dated as of June, 2002 between Safeguard Delaware, Inc. and XL Vision, Inc.

^{*} All Executive Officers and Directors are U.S. Citizens.